WOCKPHARMA Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > wockpharma

Technical Analysis

Technical Strength: 5.1 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 53.7. According to RSI analysis, wockpharma is technically strong. 9.0 WOCKPHARMA RSI Chart
MACD (?) MACD: 34.2 and Signal Line: 46.2. According to MACD analysis, wockpharma is marginally weak. 3.0 WOCKPHARMA MACD Chart
Simple Moving Average (?) According to simple moving average analysis, wockpharma is facing resistance from it's 20-day simple moving average at 925.925 and support level is at 808. 3.0 WOCKPHARMA Simple Moving Average Chart
Exponential Moving Average (?) Price just got below it's 20-day exponential moving average which is a negative signal. According to exponential moving average analysis, wockpharma is facing resistance from it's 20-day exponential moving average at 905.3618 and support level is at 830. 2.0 WOCKPHARMA Exponential Moving Average Chart
Bollinger Bands (?) %b is 0.32. 5.0 WOCKPHARMA Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 885.176 and 846.0. Resistance level is 1012.0. 6.5 WOCKPHARMA Fibonacci Retracement Chart
Average True Range (?) ATR: 42.8 NA WOCKPHARMA Average True Range Chart
Average Directional Index (?) ADX is 39.1 which means WOCKPHARMA is in a trend. NA WOCKPHARMA Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
January 19, 2018
Open Price 910.0
High Price 929.4
Low Price 886.2
Close Price 904.45
Absolute Change -8.8
Percentage Change -0.964%
Weekly Change -4.7%
Monthly Change 1.15%
Yearly Change 31.4%
52-week high 1012.0
52-week low 530.65
Corporate Actions
ExDate Purpose
July 24, 2017 ANNUAL GENERAL MEETING
November 17, 2016 INT DIV RS 10/- PER SHARE
November 17, 2016 INTERIM DIVIDEND
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.989
Confidence in Beta4.37%
Market Capital Rs. 9993.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 18.68
TTM Price-to-Earnings (P/E) Ratio 48.4
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 19 January 2018: Deliverable Quantity:2.04e+05 NA WOCKPHARMA Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 19 January 2018: Daily Volatility:0.5502 NA WOCKPHARMA Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 19 January 2018: PCR_OI:0.554 PCR:0.352 NA WOCKPHARMA PCR Chart
Option Pain (?) 19 January 2018: Max Pain:940.0 NA WOCKPHARMA Option Pain Chart
Premium (?) 19 January 2018 Premium: 2.65 Futures OI:3148200.0 NA WOCKPHARMA Premium Chart
Option_MAX_OI (?) 19 January 2018: Price:904.45 Put with maximum OI:400.0 Call with maximum OI:1000.0 NA WOCKPHARMA Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
January 25, 2018 907.1 3148200.0 2837.0 3183.0 904.45
February 22, 2018 911.0 400500.0 511.0 664.0 904.45

Announcements

November 28, 2017 Allotment of Securities Wockhardt Limited has informed the Exchange regarding allotment of 33600 securities pursuant to ESOP/ESPS at its meeting held on November 28, 2017
October 30, 2017 Appointment Wockhardt Limited has informed the Exchange regarding Appointment of Ms Zahabiya Khorakiwala as Non- Executive Director of the company w.e.f. October 30, 2017.
See all Announcements

Board Meetings

Date Meeting Date Purpose
January 15, 2018 January 29, 2018 Results Inter-alia, to consider and approve the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended December 31, 2017.
October 10, 2017 October 30, 2017 Results inter-alia, to consider and approve the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2017.
See all Board Meetings

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 840.8 Rs. 863.5 Rs. 884 Rs. 906.7 Rs. 927.2 Rs. 949.9 Rs. 970.4